PRESENTED AT AACR 2024

Miniaturizing patient-derived organoid screening assays for predictive drug testing

Colorectal cancer (CRC) is the third leading cause of cancer incidence and mortality, often with limited treatment options and significant side effects for metastatic patients. There is a critical need for more effective preclinical models to predict patient responses. Patient-derived organoids (PDOs) derived directly from patient tissue offer a breakthrough in preclinical modeling by faithfully representing the disease. While PDO technology is promising for preclinical drug screening, there is a need to expedite the transition from diagnosis to delivering PDO-based results to benefit patients directly. Through collaboration with Yamaha Motor, an automated transfer system called YAMAHA CELL HANDLER (YCH) has been optimized for handling PDOs with enhanced precision and efficiency. An image-based readout system has been developed to quantify organoid numbers to ensure assay quality precisely. A proof-of-concept study on PDO responses to chemotherapy was conducted using this automated platform, demonstrating a strong correlation between PDO and patient responses. This highlights the potential of the developed automated platform for predictive drug testing.

Download this poster to discover:

• The application of HUB Organoids to predict patient response to treatment
• The automation and optimizations that allow us to minimize human error and increase the reproducibility of our screening platform
• The real-data that shows the correlation between PDO and patient response to chemotherapy